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Abstract
Introduction: Substance use is an important risk factor for HIV, with both concentrated in certain vulnerable and margin-
alized populations. Although their management differs, there may be opportunities to integrate services for substance use
and HIV. In this paper we systematically review evidence from studies that sought to integrate care for people living with HIV
and substance use problems.
Methods: Studies were included if they evaluated service integration for substance use and HIV. We searched multiple
databases from inception until October 2015. Articles were screened independently by two reviewers and assessed for risk of
bias.
Results and discussion: 11,057 records were identified, with 7616 after removal of duplicates. After screening titles and
abstracts, 51 met the inclusion criteria. Integration models were categorized by location (HIV, substance use and other
facilities), level of integration from mirco (integrated care delivered to individuals) to macro (system level integrations) and
degree of integration from least (screening and counselling only) to most (care for HIV, substance use and/or other illnesses
at the same facility). Most reported descriptive or cohort studies; in four randomized control trials integrated activities
improved patient outcomes. There is potential for integrating services at all facility types, including mobile health services.
While services offering screening only can achieve synergies, there are benefits from delivering integrated treatment for HIV
and substance use, including ease of referral to other mental health and social services.
Conclusions: Our review used a wide range of databases and conference archives to increase representation of papers from
low- and middle-income countries. Limitations include the overrepresentation of studies from the United States, and the
descriptive nature of the majority of papers. The evidence reviewed shows that greater integration offers important benefits
in both patient and service outcomes but further research and outcome reporting is needed to better understand innovative
and holistic care models at the complex intersection of substance use and HIV services.
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Introduction
People living with HIV often have other health-related pro-
blems, either as a consequence of immune suppression,
treatment effects, shared risk factors, or a combination
thereof [1–4]. This recognition has stimulated interest in
the scope for integrating services traditionally provided
separately where there is demonstrable patient population
overlap. One such area is the intersection of substance use,
especially involving exchange of blood, and the risk of HIV.
Persons Who Inject Drugs (PWID) are 22 times more likely
to acquire HIV than adults in the general population [5].
Indeed, despite decreasing global HIV transmission, PWID in
many regions are experiencing marginally increasing HIV
infections and worldwide an estimated 1.7 million PWIDs
live with HIV [6–9]. PWID often face service exclusion, poor
or fragmented care access and discrimination, which when
coupled with punitive laws and reluctance to fund harm
reduction programs, contribute to their growing HIV burden
[9]. The overlap with substance use extends beyond inject-
ing drug use, heavy episodic drinking of alcohol has been
linked to risk behaviours such as unsafe sex and other drug
use [10,11]. Although the clinical management of HIV and
substance use differ, there is, theoretically, a case for
exploring synergies in their management; however, caution
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and contextual sensitivity are warranted as there is no
universal formula for integration, the overlap between con-
ditions is only partial and in many societies both are stig-
matizing in different ways [7].
The argument for service integration partially draws on
general interest in health services integration, both at the
policy level, where programs addressing single health pro-
blems can be brought together, and at the operational
level, ensuring efficient use of scarce resources; thereby
offering a way to improve access, responsiveness to
patients’ needs, increase coverage, reduce inequalities,
and improve health outcomes [12]. Integration is seen as
particularly promising in high HIV burden and low resource
settings, helping ensure complex health needs are
addressed, building on care delivery and drug distribution
system commonalities, facility sharing, and aligning funding
mechanisms [13,14].
Calls to integrate HIV services with services for other
health needs, such as the growing burden of non-com-
municable diseases (NCDs) in ageing populations living
with HIV, have been relatively uncontentious. However,
substance use presents a complicated situation as illicit
drug policies are highly contested. Some governments
advocate a criminal justice response and others a public
health response. In 2016, governments attending the UN
General Assembly Special Session (UNGASS on the World
Drug Problem) reaffirmed their commitment to policies
prohibiting the production, trafficking, possession and
use of illicit drugs, nevertheless they have committed
to provision of medical assisted therapy and clean inject-
ing equipment [15,16]. The 2016 UN Political Declaration
on HIV and AIDS, while acknowledging progress in
health-related risk and harm reduction programs in
some countries, noted the worldwide need for progress
in reducing PWID HIV transmission and called for com-
mitment to tailored prevention interventions [17]. This is
echoed by the Johns Hopkins-Lancet Commission on
Drug Policy and Health which calls for a harm reduction
response, drawing on a growing body of evidence of
effectiveness and embedded in a commitment to
human rights [18].
While recognizing the need to consider how political
factors may influence service integration, this review is
part of a larger review that questioned when and in what
circumstances are there benefits to bringing non-commu-
nicable disease and HIV services together. Consequently, in
this paper we systematically review evidence from studies
that sought to integrate care for people living with HIV and
substance use problems.
There have been several global and regional level systema-
tic reviews of HIV amongst PWID. However, these differed in
scope and focus, examining the two conditions’ epidemiology
[19–21] or treatment adherence determinants [22]. One
assessed the impact of alcohol use disorders on HIV medica-
tion adherence, health care utilization and treatment out-
comes while two, focusing on Africa, explored the association
between alcohol use and HIV infection risk [23–25]. None, to
our knowledge, has looked at integrating HIV and substance
use services and programs.
Methods
Definitions
We drew on the integration definition proposed by Briggs,
Atun and Legido-Quigley [26–28] whereby managerial or
operational changes to health systems bring together inputs,
delivery, management and organization of particular service
functions with the aim of improving coverage access, quality,
acceptability and/or (cost)-effectiveness. We included studies
describing: service integration interventions; service delivery
point integration; different levels of service delivery integra-
tion; process modifications; introduction of technologies
aimed at aiding integration; and integration of management
decisions [29,30]. We drew on an integration typology defin-
ing “service integration” as that integrating different clinical
services through teams of multidisciplinary professionals and
“clinical integration” as that integrating care into a single or
coherent process with shared guidelines and protocols
within and/or across professionals [31]. This typology differ-
entiated integration at the macro level, as involving integra-
tion of the health system or major elements within it; the
meso level, as involving organizations or professionals work-
ing together delivering integrated care to particular groups
or populations, and the micro level, as involving providers
delivering integrated person-centered care to individuals
(Box 1) [31].
Inclusion criteria
The review was conducted in accordance with PRISMA
guidelines. We included quantitative and qualitative stu-
dies, as well as conference abstracts that reported the
effects of health system level arrangements (service char-
acteristics, interventions, policies or programmes) in differ-
ent integrated care models for adults living with HIV and
substance use. All studies describing or evaluating a man-
agerial or organizational change to an existing health sys-
tem that sought to increase integration of HIV and
substance use services were included. For the present pur-
poses we include within substance use harmful or hazar-
dous psychoactive substances, alcohol and illicit drugs
(morphine, heroin, tramadol, oxycodone and methadone)
including non-medical use of prescription drugs.
Companion papers (under review) discuss studies integrat-
ing mental health conditions or chronic medical conditions
care with HIV.
We did not exclude reports based on study design; nor
did we require outcome measures. There were no date or
language restrictions. Studies that met inclusion criteria for
this review were in English, French and Spanish language.
No studies were excluded based on degree of assessed
bias, although this was noted in interpreting the findings.
Search strategy
The search strategy was developed with an information spe-
cialist for consistency with methods used in other health ser-
vices integration systematic reviews [28,30]. The databases
Global Health, Medline and Embase were searched from incep-
tion until October 2015. Key words (MeSH terms) and free text
terms were developed for three themes: HIV, integration and
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chronic diseases and combined in the search strategy
(Supplemental File 1). To ensure coverage of low- and middle-
income countries, databases were searched using a simplified
search strategy: Cochrane library, LILACs, Africa Wide,WHOLIS
and abstracts from the International AIDS Society (IAS) Online
Resource Library (2006–2015), the HIV Implementers meetings
(2007–2012) and international conferences on NCDs including
the 2014 Annual Meeting of the College on Problems of Drug
Dependence and the 2015 Annual Scientific Meeting of the
Research Society on Alcoholism among others.
Search and retrieval of studies
Two reviewers independently reviewed the list generated
by the electronic database search to identify relevant arti-
cles by title or title and abstract. Two reviewers indepen-
dently assessed retrieved articles to determine whether
they met inclusion criteria. Disagreements were resolved
by discussion with a third reviewer.
Data synthesis
Four reviewers independently extracted data from included
studies using standardized forms developed to capture
qualitative and quantitative study characteristics and
results data. Data extraction or study interpretation differ-
ences were resolved by discussion and consensus. Data
were extracted including information on: (1) study charac-
teristics (study design, setting and sample size); (2) partici-
pants characteristics (age, gender, ethnicity and country of
origin); (3) program or intervention integration activities;
(4) results and outcome measure type (clinical, procedural
and behavioural outcomes); and (5) integration activities’
advantages and disadvantages. Data were compared and
disparities resolved. We conducted a narrative synthesis of
study findings whereby after data extraction and using the
extraction table we reviewed and sorted the studies into
emergent groups. These groupings, which were based on
location of the integration, then informed creation of the
models.
Risk of bias assessment
Four reviewers independently assessed risk of bias in stu-
dies that reported evaluative findings using the Cochrane
risk of bias tool for randomized studies, a simple observa-
tional study proforma or an adapted checklist for
Box 1. Illustrative examples of integration typologies
Micro Meso Macro
Clinical integration
Single or coherent process
delivered by a provider who
is equipped with shared
guidelines and protocols
A physician in a methadone
maintenance program clinic
also provides HIV counselling
and testing services
A nurse working in a mobile
health van for underserved
populations is trained to
provide both HIV counselling
and DART with a clear referral
pathway to a partnering HIV
clinic, as well as substance use
counselling with a clear referral
pathway to a methadone
maintenance clinic
N/A
Service integration
Teams providing different
clinical services within the
same organisation
An HIV/AIDS clinic employs a
substance use counsellor and
physician and provides a
methadone maintenance
program for patients
A substance use program offering
needle exchange sites hires HIV
counsellors to provide
outreach, education and
referral to communities that
utilize needle exchange services
N/A
Systems integration
Coordination between multi-
location, multi-professional
organisations to develop
systems for the delivery of
services for multiple
conditions
N/A N/A The HIV/AIDS Bureau, the Bureau
of Drug Rehabilitation and
the Bureau of Communicable
Disease Control collaborate
together and coordinate with
their service providers,
community members and
stakeholders to enact policies
and shared plans to decrease
fragmentation of care for
HIV/AIDS, substance use and
hepatitis care
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qualitative studies [32]. We classified studies that had low
risk of bias in all domains as low overall risk of bias. Studies
that had high or unclear risk of bias in one or more domains
were classified as overall high or unclear risk of bias.
Results and discussion
Database searching identified 11,057 records, with 7616
remaining after duplicate removal, screened for inclusion
by title and abstract, yielding 340 articles which were
retrieved as full texts (Figure 1). Fifty-one articles met
eligibility criteria, of which 47 were articles and four
conference abstracts. We did not conduct a meta-analysis
due to heterogeneity of study design, interventions, parti-
cipants and outcomes, but instead present a descriptive
summary of interventions, results and where available,
outcomes.
Models of integration
Integration models were defined by entry point at which a
patient receives care; HIV facilities, substance use facilities
and other facilities. We identified three integration types
within these models (Figure 2). Type 1 integration includes
facilities combining screening and counselling without
Figure 2. Models of integration of HIV and substance use services.
Records identified through data base 
searching (n=11,057)
Duplicates removed 
(n=3,441)
Records screened by title and abstract 
(n=7,616)
Full-text articles assessed for 
eligibility 
Full-text articles excluded 
(n=189)  
Studies included  
(n=51)  
Records excluded 
(n=7,276)
Figure 1. Study flow diagram.
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further shared service provision. We consider screening-
only to be least integrated, as it is less resource intensive
and less complex than other forms of integration. Type 2
integration incorporates some treatment aspect, such as
antiretroviral therapy (ART) provision in substance use facil-
ities or substance use treatment in HIV facilities. The most
integrated type combines substance use and HIV treatment,
with other health care provision or social services; for
example, drug and HIV treatment integration with harm
reduction and palliative care [33,34].
Characteristics of included studies
Fifty-one papers met the inclusion criteria; 22 papers
described integration at HIV facilities, 20 at substance use
facilities and seven at other facilities (sexually transmitted
disease (STD) clinic, syringe access sites, emergency depart-
ment and mobile health van). Two papers discussed
patients’ perspectives on integration as a broader concept.
Across sites, 11 involved screening activities, 29 treatment
integration, and nine included services for other comorbid-
ities. There were 18 descriptive studies; 14 cohort studies,
seven qualitative studies, four RCT’s, one case-control, two
mixed-methods and one cost analysis.
The majority of studies (n = 39) were conducted in the
United States of America (USA) with two in Canada [33–74].
There were four European studies, two from Spain, one
from Ireland and one from the Ukraine [75–78]. Two stu-
dies were from Africa, one each from Kenya and Tanzania
[61,79]. There were four studies from Asia, one each from
India, Indonesia, Taiwan and Vietnam [80–83]. The USA
studies integrated care in all three facility types. Of the 41
studies from North America, 21 were located in HIV facil-
ities. Elsewhere, only Kenya reported integration in an HIV
facility [61]. Beyond North America, the majority of studies
were in substance use facilities. Of ten non-North American
studies, six were located in substance use facilities
[75–77,79,80,82].
Most integration examples were from areas with a low to
moderate burden of HIV infection amongst people who
inject drugs (PWID); no studies were from countries with
over 50% of PWID living with HIV (Figure 3). Studies from
Indonesia, Spain and Tanzania, which fall in the moderate
range of PWID living with HIV (25.01–50%) involved HIV
care integration into drug treatment programs [76,79,80].
Examples from countries with a lower range (10–25% PWID
living with HIV) such as Canada, Kenya, and the Ukraine
involved integration into HIV facilities, except for Ireland
which integrated HIV services into addiction services
[33,34,61,75].
Published examples were mostly from countries that
allow access to both methadone (MMT) and buprenorphine
maintenance treatment (BMT); only two studies were from
areas that only offered MMT – Kenya and Vietnam [61,83].
India, which only offers BMT, was represented in one
study [81].
Six papers offered an integration definition
[45,55,57,63,69,75]. Two papers drew on Blount’s inte-
grated service criteria where medical and behavioural ele-
ments are integrated into a treatment plan [57,63] and the
remaining papers provided alternate definitions and criteria
(Table 1).
Integrations occurred at all system levels, but most (n = 30)
describedmicro level service integration [33–41,44,47–49,51–
53,57–59,61–63,66–71,76,77,79,80,82] (Table 2). Within HIV
facilities, 15 studies explored micro level integration [33–
37,48,49,52,61–63,67,69–71], one described meso level clin-
ical integration [60] and five described macro level integration
[45,50,57,73,74]. Similarly, within substance use facilities, the
majority of studies were micro level integrations (n = 12)
[40,41,44,47,51,58,59,66,68,76,77,79,80,82], with three
meso level integrations [46,56,65]. In other facilities, three
studies described micro level integration [38,39,53], two
described meso level integration [42,43] and two described
macro level integration [55,78].
Figure 3. Map of integration by type and prevalence of HIV amongst persons who inject drugs.
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Risk of bias assessment
We conducted risk of bias assessments for studies that eval-
uated service integration and reported outcome measures or
qualitative results (Supplemental File 2). This included 23
studies; 13 cohort studies [36–40,42,62,63,66,68,76,79,80],
four randomized control studies [35,52,61,69], two cross sec-
tional studies [75,77], two qualitative studies [48,57], one case
control study [59], and one cost analysis [67]. Fifteen had high
risk of bias [36,37,39,40,48,62,63,68,69,75,77,79,80], six had
moderate risk of bias [35,42,52,61,66,76] and two had low risk
of bias [57,59].
Model 1: integration of substance use services at an HIV
facility
Twenty-two studies described integrated HIV and substance
use care at HIV facilities. We define an HIV facility as an HIV
clinic, HIV primary care clinic or other health care setting
established to deliver HIV care. Within this model, the HIV
facility offers different activities for substance use screening
or treatment (Table 3).
Type 1: substance use screening at an HIV facility
One study reported only substance use screening within an
HIV clinic in the USA, where electronic medical record scan-
ning identified patients misusing substances and clinic staff
referred them for substance or mental health evaluation [60].
Type 2: substance use treatment at an HIV facility
Eighteen papers incorporated substance use screening with
treatment, including 10 studies from the USA that used
buprenorphine naloxone (BUP/NX) for treatment. One
sought to determine feasibility and efficacy of BUP/NX
and psychosocial support in an HIV clinic, with no clear
results [69].
Six papers reported on the American Buprenorphine HIV
Evaluation and Support Initiative (BHIVES), which inte-
grates BUP/NX into HIV care and involves a multisite
evaluation with cross-site education and support [74].
Nine sites reported positive perceptions and described
successful integration despite challenges with patient
comorbidities and organizational barriers to program
implementation, such as incorporating new procedures
into established practice and limited adoption [73].
Patients had positive perceptions of BHIVES and attributed
greater engagement with both HIV and substance use care
to the integration [49]. Other studies reported positive
perceptions of BUP/NX integration and the importance
of counselling and social support in conjunction with phar-
macological treatment [48].
Seven papers described counselling-focused interven-
tions at HIV facilities. Telehealth motivational interviewing
(MI) was used in three studies, two aiming to reduce
drinking and one to reduce drug use; all reported positive
patient outcomes [35,36,52]. One study explored an MI
intervention, one a cognitive behavioral therapy (CBT)
intervention and two described a combination MI and CBT
approach provided to HIV patients at HIV facilities with
positive results [61–63]. One study, conducted at HIV facil-
ities in the USA, explored provider perceptions of clinic
Table 1. Definitions of integration from studies included in
the review
Author Definition of integration
Lombard et al. [57] and
Proescholdbell et al. [63]
Blount (2003) criteria: integration of
behavioural and medical elements
into one treatment plan
Cheever et al. [45] Integration as an ongoing process
requiring assessment, planning,
intervention and evaluation
Bachireddy [75] Integration occurring on a spectrum
with service co-location as
“simple” integration and cross-
disciplinary case management as
more integrated
Sullivan [69] Provider integration, where
integration at the clinic level
involves those services provided by
different clinicians occurring at a
single site, whereas individual
integration is one where the
treatment service is provided by
the same clinician at a single site
Hoffman [55] A formalized, collaborative process
among services and systems with
the goal of decreasing
fragmentation of care and
improving coordination
Table 2. Overview of integration type by model from studies
included in the review
Integration
location Integration type n =
HIV facility Micro-service integration [33–
37,48,49,52,61–63,67,69–71]
15
Macro-systems integration [33–
37,48,49,52,61–63,67,69–71]
5
Meso-clinical integration [60] 1
MLa [72] 1
Substance use
facility
Micro-service Integration
[41,44,47,51,58,59,66,68,76,77,79,80]
12
Meso-clinical integration [46,56,65] 3
ML [54,64,75] 3
Micro-clinical integration [40,82] 2
Other facility Micro-service integration [38,39,53] 3
Meso-clinical integration [42,43] 2
Macro-systems integration [55,78] 2
Patient
perspectives
ML [81,83] 2
aML describes those studies that explored multiple levels.
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adaptations to integrate counselling; barriers including
clinic size differences, space constraints, services offered,
process design, professional autonomy and multidisciplin-
ary team communication and collaboration [57].
Type 3: substance use treatment + other treatments at an
HIV facility
Four of 22 studies at HIV facilities described HIV care and
substance use integration involving comorbidity treatment or
a harm prevention approach. Two studies incorporated
hepatitis C virus infection (HCV) care using a multidisciplinary
model merging addiction, psychiatry, HIV and HCV treatment
at a Centre for AIDS Research Coinfection Clinic [70,71]. Two
studies from Canada explored an HIV day health and resi-
dential program providing medical care, counselling, social
service referrals and a supervised injection program; staff
reported greater trust and patient engagement, and patients
felt supported in their safe injection habits, while social and
structural determinants of health were better met, increas-
ing treatment adherence [33,34].
Model 2: integration of HIV services at substance use
facilities
Twenty studies described care for HIV and substance use
provided at substance use facilities (Table 4). Our definition
of a substance use facility is a drug addiction/misuse/use
centre or other healthcare setting primarily aiming to treat
or mitigate the effects of drug addiction/misuse/use.
Type 1: HIV screening and prevention counselling at a
substance use facility
Eight studies integrated HIV prevention counselling and
screening at substance use facilities. One abstract described
counselling without HIV screening in an MMT program in
Taiwan [82]. Six papers described programs integrating
prevention counselling with HIV screening activities. One
paper provided an overview of state-wide integration of
Table 3. Summary of integrations provided at HIV facilities
Type Activity Author n =
1. Substance use screening Screening O’Neill 2007 (USA) 1
2. Substance use treatment BUP/NX Cheever 2011 (USA), Turner 2005 (USA), Weiss 2011A
(USA), Weiss 2011B (USA), Altice 2011 (USA), Finkelstein
2011 (USA), Schackman 2011 (USA), Egan 2014 (USA),
Sullivan 2006 (USA), Draioni 2014 (USA)
10
Counselling/MI Hasin 2013 (USA), Aharanovich 2006 (USA), Aharanovich
2012 (USA) Lombard 2009 (USA), Proschold-Bell 2010
(USA), Parsons 2005 (USA), Papas 2011 (Kenya)
7
3. Substance use treatment + other treatments HCV treatment Taylor 2005 (USA), Taylor 2012 (USA) 2
Residential Care Krusi 2009 (Canada), McNeil 2014 (Canada) 2
Table 4. Summary of integrations provided at substance use facilities
Type Activity Author n =
1. HIV screening and
prevention counselling
● Prevention counselling
only
● Lee 2015 (Taiwan) 1
● Screening and
prevention counselling
● Seewald 2013 (USA), Kmeic 2012 (USA),
Conners 2012 (USA), Henry 2010 (USA),
Cartter 1990(USA), Gunn 2005 (USA)
6
2. HIV treatment ● Nurse led intensive
care coordination
● Andersen 2003 (USA) 1
● Pharmacological treatment ● Surah 2012 (Ireland), Sanchez 2012 (Spain),
Cooperman 2007 (USA), Achmad 2009
(Indonesia), Berg 2009 (USA), Lucas 2004
(USA), Lucas 2007 (USA), Sorensen 2012
(USA), Tran & Bruce 2015 (Tanzania)
9
3. HIV treatment
and other care
services
● Bachireddy 2014 (Ukraine), Selwyn 1993
(USA), Rothman 2007 (USA)
3
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HIV services with MMT programs, indicating efficacy in
testing linked to pre- and post-test counselling in substance
use treatment facilities [44]. Another found evidence of
efficacy of HIV and hepatitis B (HBV) counselling and test-
ing, as well as HBV vaccination, in high risk patients in a
non-residential drug-rehabilitation program [51]. Four of six
studies from the USA focused on integrating rapid HIV
testing into substance use treatment facilities. A study of
patient acceptance in an ambulatory detoxification setting
in the USA found rapid testing was acceptable to those with
alcohol and opioid use [56]. Two studies from American
Veterans Health centres that explored nurse led HIV rapid
testing implementation found positive staff perceptions and
readiness to provide HIV rapid testing. Reported barriers
included increased staff workload, staff hesitancy perform-
ing medical procedures, and anxiety delivering HIV-positive
results, as well as challenges linking patients to off-site HIV
care [46,65].
Type 2: HIV treatment at a substance use facility
Ten studies integrated HIV treatment at substance use
facilities. One study from the USA described promising
results from a nurse-led intensive care coordination
protocol, where nurses accompanied participants for HIV
treatment and facilitated integration of medical recommen-
dations with substance use treatment [40].
Nine studies explored integrating pharmacological treat-
ment (ART, HAART or DAART) into substance use treatment
facilities. One prospective cohort study from Spain assessed
HAART effectiveness at a drug use out-patient centre, where
active drug users in the program achieved virological suppres-
sion rates on par with non-drug using matched subjects [76].
Seven studies explored HIV treatment in MMT programs. In
Indonesia, an MMT program offered ART which improved HIV
case detection and ART uptake [80]. Two studies in the USA
offered HAART and directly observed therapy (DOT) treat-
ment options to current and former opioid users in an MMT
program, but with no clear results [41,47]. However, three
studies from the USA explored integrating DAART into MMT
programs in outpatient substance use treatment facilities with
positive results for virological suppression; all
faced participant drop out and poor adherence challenges
[58,59,68]. In Tanzania, a study at an MMT that dispensed
ARTs found evidence that methadone use enhanced client
retention and linkage to care [79]. From a staff perspective, a
study in Ireland of 30 addiction staff with HIV clinic links
explored attitudes 6 months post integration showing positive
staff perceptions of patients and of the integration [77].
Type 3: HIV treatment + other conditions at a substance
use facility
Three studies described integration of HIV and substance
use treatment with management of other conditions, at
substance use facilities. One study from the Ukraine
assessed three integration models addressing substance
use, HIV and TB, suggesting greater service integration
increases ART access and improved patient quality of life
[75]. In the USA, two studies explored primary care provi-
sion for HIV-infected drug users at substance use facilities
with positive results; however, treatment paradigm differ-
ences between substance use and HIV care were reported
as challenging to integration [64,66].
Model 3: integration of HIV and substance use services at
other facilities
Integration activities took place at five other facility types
described in six papers, while one paper described a multi-
location macro health systems integration of HIV, substance
use and other services (Table 5).
Two studies took place in clinical settings; one STD clinic
and one emergency department. Both described HIV testing
and prevention counselling amongst substance using
patients and reported improved HIV testing uptake [42,53].
Three studies were located at harm reduction sites or
mobile locations. One study from the USA explored a nurse-
led health promotion program at syringe access sites and
described efficacy in reaching large numbers of PWID [43].
Two studies described a mobile health clinic in the USA that
provides HIV counselling, case management, drug treat-
ment coordination, health status assessment, and medical
care [38,39]. The papers reported improved virological
results in patients receiving HAART and following DAART
introduction, reported patient preference for mobile site
treatment.
One paper described a patient-centered integration in
Spain, offered jointly through the AIDS Patient Homecare
Program (PADS) and Red Cross drug addiction program,
delivered at patients’ preferred location[78]. PADS coordi-
nated medical, substance use and comorbidity care and
multiple social supports for patients and their families;
reporting that substance use treatment, mainly through
methadone, was important in patient success.
One paper described a systems level initiative in the USA,
integrating service provision between government bureaus
for HIV/AIDS, substance use and communicable diseases
[55]. The main program output was a strategic plan offering
Table 5. Summary of integrations provided at other facilities
Location Type Author n =
Syringe access site • HIV prevention
counselling
• Burr 2014
(USA)
1
STD clinic • HIV Testing • Hennessey
2007 (USA)
1
Emergency dept • HIV Testing &
Prevention
Counselling
• Bernstein
2012 (USA)
1
Mobile • HIV Treatment • Altice 2003
(USA), Altice
2004 (USA)
2
Multiple – patient
centered
• HIV Care • Tato 2000
(Spain)
1
Systems integration • HIV + Substance
Use + Mental
Health + Hepatitis
• Hoffman
2004 (USA)
1
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joint assistance and provider training, coordination and
information access, as well as joint procurement processes
and contracting services.
Patients’ perspectives
Two papers described patients’ perspectives on integrated
HIV and substance use services, regardless of patient entry
point. One cross-sectional study from Vietnam explored 510
MMT patient perspectives on integrated and decentralized
MMT clinics and reported high preference for integration
[83]. In India, a qualitative study explored HIV-positive
PWID barriers to ART access and reported complex indivi-
dual, social and system barriers while calling for supports
built into existing treatment options [81].
Measures of effectiveness of integration
32 studies evaluated one or more measures of effective-
ness of the integrated intervention, program or model. We
Table 6. Types of outcome measures reported
Types of outcomes reported
(n = number of studies reporting outcomes)
Models of integration Patient outcomes Service delivery outcomes
HIV facility
(n = 22; n = 16 reported
outcomes)
● Identified with substance misuse disorder (1)
● ART uptake (1)
● ART adherence (2)
● BUP/NX adherence (1)
● CD4 count (2)
● Virological suppression (2)
● ASI score (2)
● Patient satisfaction and perspectives (5)
● Substance Use – Opioid (1)
● Substance Use – general (3)
● Number of Drinks per Day (3)
● Percentage drinking days (1)
● IVR Calls made (1)
● Confidence & temptation scores (1)
● Referral to substance use or mental health
evaluation (1)
● Median monthly provider encounters (1)
● Median monthly clinic costs per integrated
care patient (1)
● Median monthly costs for BUP/NX (1)
● Staff satisfaction and perspectives (3)
Substance use facility
(n = 20; n = 13 reported
outcomes)
● HIV testing acceptance (2)
● # rapid HIV tests performed (3)
● # newly diagnosed with HIV (1)
● Appointment adherence (1)
● Counselling adherence (1)
● Days to follow up (1)
● ART initiation (2)
● ART adherence (2)
● Hep B vaccination uptake (1)
● Receiving OST (1)
● ASI (1)
● Substance use (2)
● Global Well Being Scale (1)
● QHI composite scores (1)
● Perception of physical health, social functioning and
mental health (1)
● Probability of CD4 screening (1)
● CD4 count (1)
● Virological suppression (3)
● Probability of virological response (1)
● Retention (2)
● Survival (1)
● Frequency of clinic visit (1)
● Staff satisfaction and perspectives (2)
● Total annual cost per client served (1)
● Quality review (1)
Other Facility
(n = 7; n = 3 reported
outcomes)
● Percentage of unprotected sex acts (1)
● Percentage of sex acts while high (1)
● Mean CD4 (1)
● Virological suppression (1)
● Entry to drug treatment (1)
● Percentage of ART doses taken (1)
● Rates of adherence (1)
Patient Perspectives
(n = 2; n = 0 reported
outcomes)
N/A N/A
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define patient outcomes as a change in patients’ health
status, knowledge, behaviours or attitudes. We define ser-
vice delivery outcomes as measures reflecting effectiveness
in delivery of the service, program or integration, including
staff perceptions (See Table 6).
One study reported long term outcomes of a macro
integration from an organizational quality perspective
[64]. Eight studies within HIV facilities were qualitative,
reporting patient or staff perceptions of integration
[33,34,48,49,57,73,81,83]. Two studies provided cost ana-
lyses, reporting on total integration cost as well as cost per
client [51,67]. One study looked at three substance use
disorder clinics and found that six months post rapid HIV
testing implementation, acceptance rates and HIV testing
were higher at the most integrated site [46]. Another study
assessed different integration models, and reported Health
Quality of Life (HRQoL), Quality Healthcare Index (QHI)
composite scores and likelihood of patients’ receiving ART
and opioid substitution therapy (OST) found patients receiv-
ing integrated care had significantly higher QHI scores
compared to those receiving non-collocated services or
harm reduction only (71.9% versus 54.8% versus 37.0%,
p < 0.001); patients receiving integrated care were signifi-
cantly more likely to receive ART (49.5% versus 19.2%,
p < 0.001) [75].
Nineteen intervention studies were included [35–
40,42,52,59,61–63,65,66,68,69,76,79,80]; 14 were cohort
studies; two had a control group receiving usual care
[76,80] one compared against seronegative patients [66]
and 11 compared against baseline data [36–
40,42,62,63,65,68,79]. One study was a case-control [59].
Four were RCTs [35,52,61,69], one compared a control
(usual care group) with two intervention arms [52], one a
usual care group against one intervention group [61]. Two
papers compared two intervention groups against each
other with no usual care control. All studies reported
results pointing to positive outcomes from integration, but
had high or moderate risk of bias; therefore while out-
comes show promising results, the high risk of bias war-
rants caution in making assumptions on efficacy
(Supplemental File 3).
Discussion
This review explores different approaches to integrated HIV
and substance use services based on patient entry points,
synthesizing integration evidence at HIV, substance use and
other facilities, as well as patient perspectives. The extent
of integration varies, from combined screening activities to
fully integrated screening, treatment and referrals for HIV,
substance use and other comorbidities.
These models have advantages and disadvantages
(Table 7). A positive finding is that across models the
potential to increase HIV and substance use detection as
well as provide structure, accountability and support for
treatment adherence has been realized in some sites. Also,
a single care provider may reduce the likelihood of drug
interactions, while integrated services can facilitate com-
munication across providers. When HIV, substance use and
other conditions are managed together, enhancing
continuity of care, there is evidence that acute episodes
may be reduced, translating into reduced costs for patients
[38,39]. However, some studies noted challenges to inte-
gration. For example, BHIVES achieved promising patient
outcomes, but implementation barriers included higher
costs, appropriate financing, workforce training, and chal-
lenges in combining differing clinical practices. Further,
there is evidence that staff at substance use facilities may
be hesitant to perform HIV testing, seen as a medical
procedure, as well as in communicating positive HIV test
results to patients. Integration also requires strong referral
links to primary care, mental health and social services to
address multiple and diverse patient needs [84]. A criminal
justice approach to substance use has, in some regions,
created legal barriers limiting pharmacological treatments
and harm reduction activities [85]. Punitive approaches
make it difficult to see the individual as a patient, prevent-
ing or delaying access to care [18,86].
We identified innovative approaches including integrated
HIV and substance use care in mobile, community and
residential settings. Such programs offer a people-centered
approach allowing greater patient agency in managing sub-
stance use, HIV care and psychosocial supports. There is
need for responsive, appropriate and convenient programs
addressing the often-chaotic lives of people who use drugs
[87] and these programs show promise reaching margin-
alized groups and provide a platform to build trust, edu-
cate, provide treatment and encourage adherence.
Residential facilities have achieved success using robust
harm reduction strategies coupled with housing, medical
facilities and psychosocial support [33,34]. Other patient-
centered programs utilized intensive nurse-led care to cre-
ate coordinated protocols and foster provider-patient rela-
tionships [40]. These approaches require staff to be
treatment advocates, use multidisciplinary approaches and
have adequate access to not only mental health and clinical
resources but social, transport and housing linkages
[40,88,89].
Of note is the evidence describing patient perspectives of
systems without integrated services, where patients
encounter multiple family, social and system level barriers
to care [81,83]. Patients reported fear of discrimination,
unmet basic needs and unfriendly hospital environments
and procedures, with inadequate counselling and perceived
lack of confidentiality [81]. In contrast, studies describing
fully integrated harm reduction approaches reported posi-
tive patient perceptions, especially of holistic care provision
to address unmet social needs [33,34].
Strengths and limitations
We used a wide range of databases and conference
archives to increase paper representation from low- and
middle-income countries. We also included studies pub-
lished in languages other than English. However, studies
were mostly from the USA, dealing with BUP/NX or the
BHIVES initiative. Also, the review included many descrip-
tive papers which, while providing insights into various
integrated approaches, could not be used to infer effec-
tiveness. In total 33 studies reported integration measures
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of effectiveness, four of which were RCTs in which meth-
odological quality varied and overall had high or moderate
risk of bias. Our review did not compare between inte-
grated versus non-integrated services outcomes due to
lack of literature. Further, due to the broad nature of the
review we were unable to account for differences in
treatment modalities for different types of substance use
that may impact their ability to be effectively integrated
into clinical care.
Implications for research
Our review shows that research on integrated HIV and
substance use care has focused on treatment approaches
at the meso-level and small-scale clinical integration. There
is need for further macro-level evaluations of systemic HIV
and substance use service integration. Further, there is
need to pursue research exploring meso-level integrations
focusing on shared values and the tools necessary to over-
come barriers obstructing links between HIV and substance
use care.
Overall, there is need for longer term and more robust
studies evaluating effectiveness. There is also a lack of
long-term outcomes or relevant impacts on HIV and sub-
stance use, including reduced transmission rates and over-
all mortality. The longest follow up period reported in
studies comparing outcomes was 12 months. This high-
lights the need for well-designed, robust studies with clear
outcome indicators evaluating and comparing
Table 7. Summary of advantages and disadvantages reported in studies by integration model
Model 1: HIV facilities Model 2: substance use facilities Model 3: other facilities
Potential
advantages
Substance use screening
● Potential to increase substance
use detection
● Minimal additional resources
required
Substance use treatment
● Provides structure, accountability,
support and one touchpoint to
support treatment adherence
● One treatment provider may
reduce likelihood of negative drug
interactions
● Facilitates communication across
providers
Substance use + others
● Potential to increase detection of
HIV, substance use and other
comorbidities
● Addresses social determinants
through residential care or strong
referrals
HIV screening
● Potential to increase HIV detection
and patient awareness of HIV
status
● Education platform
● Easy implementation of rapid
testing
HIV treatment
● Provides structure, accountability,
support and one touchpoint to
support treatment adherence
● One treatment provider may
reduce likelihood of negative drug
interactions
● Facilitates communication across
providers
HIV + others
● Potential to increase detection
and treatment of HIV, substance
use and other comorbidities
● Could reduce acute care episodes
for patients reducing patient cost
Clinical facilities
● Potential to increase HIV detection and
patient awareness of HIV status
● Easy implementation of rapid testing
Harm reduction and mobile facilities
● Can access and serve marginalized
groups
● Platform to build trust, teach safe
injection practice and HIV risks and
prevention
● Provides structure and one touch point
to support treatment adherence
● Facilitates communication across
providers
● Mobile clinic: perception of increased
patient confidentiality – offers a suite
of services, reduction of stigma
Patient led location
● Robust case management and identifi-
cation of comorbidities
● Could improve treatment adherence
and monitoring
● Holistic view of patient and family
needs and can link patient to other
social services
Potential
disadvantages
Substance use screening
● Requires staff training
● Loss to follow up
Substance use treatment
● Legal barriers to provision of
pharmacological treatment
● Requires strong linkages between
pharmacological and counseling
treatment
● Conceptual differences between
HIV care and substance use care
Substance use + others
● Policy and legal barriers to harm
reduction approaches
● Cost of implementation
HIV screening
● Substance use staff hesitancy at
performing HIV testing and giving
positive test results
HIV Treatment
● Requires links to primary care,
mental health and social services
● Conceptual differences between
HIV care and substance use care
treatment
HIV + others
● Cost of implementation
Clinical facilities
● Loss to follow up
● Requires staff training
Harm reduction, mobile and patient led
facilities
● Requires robust and dedicated
outreach
● Requires additional staff, staff training
and pharmacy coordination
● Loss to follow up due to patients’ social
situation, incarceration, etc.
● Requires linkage to specialty care,
acute care, mental health care and
other social services
● Requires links to local police and other
groups to map and understand the
vulnerable population
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interventions. Also, further qualitative and mixed methods
studies are necessary to better explore patient
perspectives.
There is a particular need for research on integration
approaches using model 3 whereby services are offered at
diverse locations. While many studies described HIV testing
initiatives, only one described a substance misuse screening
initiative. Further research is required on sensitive
approaches, such as community based or mobile service
delivery, for specific needs of often vulnerable, transient
and hard to reach populations. As the findings from studies
of model 3 show, people living with HIV and substance use
have diverse interactions with the health system and it is
important to understand how to screen, refer or treat
substance use in a variety of service provision settings.
Although our review included non-English papers and
aimed for broad representation, only five studies were
from low- or middle- income countries; one from
Indonesia, one from Vietnam, one from India, one from
Kenya and one from Tanzania, none from Latin America.
There is need for studies from areas with a high burden of
HIV and PWID, given their greater risk of HIV infection,
and from different regions and health systems. However,
as the lack of studies may be reflective of laws or policies
in different regions placing prohibitions on substance use,
it is important to address punitive approaches to sub-
stance use that may inhibit innovation and research on
PWID.
Conclusions
We identified three models integrating HIV and substance
use; services in HIV facilities, substance use facilities and
others. Benefits to integration are reported largely in
terms of patient outcomes, including how integrated ser-
vice can better enable patients to uptake and adhere to
treatment; there are also demonstrable service outcomes
including staff satisfaction with integrated approaches and
easier referral to mental health and social services.
Despite many countries pursuing a criminal justice
approach, the UNAIDS 2016–2021 Strategy identifies the
need to commit to service integration for those with drug
dependency. The evidence reviewed here shows the need
for innovative and holistic responses at the intersection of
substance use and HIV services, especially the provision of
integrated care at non-traditional sites and amongst vul-
nerable groups.
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